Thus our data indicated that the IL-6/IDO1 axis may play a pathogenetic role in a chronic, low-grade inflammation condition, and, perhaps most importantly, IL-6R blockade may be considered a valid option for obesity treatment. This evidence concerns the gene IL6R and obesity due to melanocortin 4 receptor deficiency.